1. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010;102:170-8.
3. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast cancer. Clinical practice guidelines in oncology 2009;7:122-92.
4. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma
in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
5. Group EBCC, Group ER, Bijker N, Meijnen P, Peterse JL, Bogaerts J, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381-7.
6. Romero L, Klein L, Ye W, Holmes D, Soni R, Silberman H, et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg 2004;188:371-6.
7. Donker M, Litiere S, Werutsky G, Julien JP, Fentiman IS, Agresti R, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma
in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31:4054-9.
8. Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, et al. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 2011;18:2873.
9. Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol 2015;1:888-96.
11. Solin LJ, Fourquet A, Vicini FA, Taylor M, Olivotto IA, Haffty B, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma
in situ of the breast. Cancer 2005;103:1137-46.
12. Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ, et al. Outcome after invasive local recurrence in patients with ductal carcinoma
in situ of the breast. J Clin Oncol 1998;16:1367-73.
14. Vicini FA, Recht A. Age at diagnosis and outcome for women with ductal carcinoma-in-situ of the breast: a critical review of the literature. J Clin Oncol 2002;20:2736-44.
15. Schouten van, Peeters PH, Koot VC, Hennipman A. Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age. Ann Surg Oncol 2006;13:990-8.
16. Rakovitch E, Nofech-Mozes S, Narod SA, Hanna W, Thiruchelvam D, Saskin R, et al. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat 2013;138:581-90.
17. Wang SY, Shamliyan T, Virnig BA, Kane R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma
in situ: a meta-analysis. Breast Cancer Res Treat 2011;127:1-14.
18. Ringberg A, Nordgren H, Thorstensson S, Idvall I, Garmo H, Granstrand B, et al. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma
in situ of the breast--results from the Swedish randomised trial. Eur J Cancer 2007;43:291-8.
19. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma
in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011;12:21-9.
20. Early Breast Cancer Trialists’ Collaborative G, Correa C, McGale P, Taylor C, Wang Y, Clarke M, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma
in situ of the breast. J Natl Cancer Inst Monogr 2010;2010:162-77.
21. Williams KE, Barnes NL, Cramer A, Johnson R, Cheema K, Morris J, et al. Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol 2015;26:1019-25.
22. Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011;126:185-92.
23. Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma
in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004;100:2317-27.
25. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma
in situ: a study based on NSABP protocol B-24. J Clin Oncol 2012;30:1268-73.
26. Mele A, Mehta P, Slanetz PJ, Brook A, Recht A, Sharma R. Breast-conserving surgery alone for ductal carcinoma
in situ: factors associated with increased risk of local recurrence. Ann Surg Oncol 2017;24:1221-6.
27. Mathew J, Karia R, Morgan DAL, Lee AHS, Ellis IO, Robertson JFR, et al. Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma
in situ. Breast 2017;31:181-5.
28. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441-52.
29. Bannani S, Rouquette S, Bendavid-Athias C, Tas P, Leveque J. The locoregional recurrence post-mastectomy for ductal carcinoma in situ: Incidence and risk factors. Breast 2015;24:608-12.